14.12.17|Lilach Baumer, Golan Hazani, and Orr HirschaugeAstraZeneca CEO Pascal Soriot, which backed out of Teva’s CEO position in July, planned on taking the company towards innovation instead of generic focus
11.09.17|Sophie Shulman, Dror ReichTroubled drugmaker says new CEO must work to quickly regain its financial credibility
06.08.17|Golan HazaniTeva’s board was surprised to learn AstraZeneca's CEO Pascal Soriot will not be joining the company. Teva activist investor Benny Landa called an early report on Teva's negotiations with Mr. Soriot "devastating"